The Latest Breaking News from ZBH

Zimmer Biomet Holdings is expected to release its third-quarter earnings later this month, and analysts expect a single-digit earnings growth.

STERIS has underperformed the S&P 500 over the past year, yet analysts remain moderately bullish about the stock’s potential.

Investing in oversold stocks can be a potentially profitable strategy for investors who are willing to take calculated risks and have a long-term perspective. Amid this backdrop, investors could consider buying fundamentally strong oversold stocks Comcast (CMCSA), Northrop Grumman (NOC), and Zimmer Biomet Holdings (ZBH) with an RSI below 30.…

The medical industry is thriving due to rising demand for healthcare products and services, fueling significant returns. Given the solid long-term prospects of the industry, let’s analyze fundamentally sound medical stocks McKesson (MCK), Zimmer Biomet (ZBH) and Fresenius SE (FSNUY).

Thanks to the rising awareness of the benefits of digital health services and technological advancements, the medical industry is poised for remarkable growth. While the industry outlook may seem promising, should one buy or sell Medtronic (MDT), Zimmer Biomet (ZBH), and Merit Medical (MMSI)? Read more to find out.

The stock market has been witnessing wild swings lately amid growing concerns over the Fed’s aggressive interest rate hikes to combat the multi-decade high inflation, supply bottlenecks, ongoing geopolitical crisis, and possibility of a recession. However, wide-moat stocks have competitive advantages and tend to outperform their peers in the long…

The stock market has witnessed a massive sell-off lately on concerns over the Fed’s aggressive interest rate hikes to fight the decade-high inflation. Many analysts expect the economy to slip into recession due to the Fed’s monetary policy tightening. Since the medical device industry is known to be one of…

Within the last quarter, Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings:

Zimmer Biomet Holdings Inc's (NYSE:ZBH) Q1 sales increased by 3.9% Y/Y to $1.66 billion (up 6.8% on a constant currency basis), beating the consensus of $1.59 billion. Adjusted EPS was $1.61, which came in above the consensus of $1.41 and $1.55 a year ago. "We are encouraged by the better than expected results…